Non-BAC Component but not Epidermal Growth Factor Receptor Gene Mutation is Associated with Poor Outcomes in Small Adenocarcinoma of the Lung  by Kobayashi, Naruyuki et al.
ORIGINAL ARTICLE
Non-BAC Component but not Epidermal Growth Factor
Receptor Gene Mutation is Associated with Poor Outcomes
in Small Adenocarcinoma of the Lung
Naruyuki Kobayashi, MD,* Shinichi Toyooka, MD,* Kouichi Ichimura, MD,† Junichi Soh, MD,*
Hiromasa Yamamoto, MD,* Keitaro Matsuo, MD,‡ Hiroki Otani, MD,* Masaru Jida, MD,*
Takafumi Kubo, MD,* Kazunori Tsukuda, MD,* Katsuyuki Kiura, MD,§ Yoshifumi Sano, MD,*
and Hiroshi Date, MD
Objective: The purpose of this study was to identify risk factors for
poor clinical outcome after surgical resection of small lung adeno-
carcinoma.
Materials and Methods: Clinical records of 127 patients who had
pathologic stage IA lung adenocarcinoma 20 mm or less and who
had undergone a lobectomy with mediastinal lymph node dissection
were reviewed. The percentage of non-bronchioloalveolar carci-
noma (non-BAC) components quantified objectively, and epidermal
growth factor receptor gene (EGFR) mutation determined by poly-
merase chain reaction-based assay were retrospectively linked with
clinical data.
Results: Based on the percentage of non-BAC component, 127
patients were classified as follows: 26 in group I, BAC, 46 in group
II mixed subtype with  50% BAC, 18 in group III, mixed subtype
with under 50% BAC, and 37 in group IV, mixed subtype with all
non-BAC components or a pure pattern of one of the non-BAC
components. Groups I and II were considered to be a “low non-BAC
component type” and groups III and IV were considered to be a
“high non-BAC component type.” EGFR mutations in exon19 and
exon21 were observed in 64 patients (50.4%). In terms of recur-
rence, the high non-BAC component type was the only independent
factor for recurrence (p  0.029). Regarding survival, the high age
(p  0.028) and high non-BAC component type (p  0.046) were
independent risk factors for poor overall survival. They were also
independent risk factors for poor disease-free survival (p  0.025
and p  0.027, respectively).
Conclusion: The high non-BAC component but not EGFR mutation
status, is an independent risk factor for both recurrence and poor
prognosis in patients with stage IA lung adenocarcinoma 20 mm.
Key Words: Lung cancer, Adenocarcinoma, Stage IA, Bronchi-
oloalveolar carcinoma, Non-BAC component, EGFR.
(J Thorac Oncol. 2008;3: 704–710)
Lung cancer is the leading cause of death from cancer inJapan and many countries.1,2 Survival among patients with
non-small-cell lung cancer (NSCLC) remains unsatisfactory
because many cases present with advanced disease and are
unresectable.3 Even patients with early stages of the disease
who undergo complete resection sometimes undergo a recur-
rence, resulting in a poor prognosis.4,5 Approximately 30% of
patients with stage IA NSCLC die within 5 years of surgery.6
Recent studies have demonstrated the usefulness of
postoperative adjuvant chemotherapy among patients with
stage IB to IIIA NSCLC who have undergone complete
resections.7–9 Kato et al. reported that adjuvant chemotherapy
with uracil-tegaful prolonged survival among patients with
stage I adenocarcinoma and a tumor diameter of greater than
20 mm. They also concluded that patients with tumor 20 mm
in diameter should be excluded from adjuvant therapy unless a
subgroup with a poor prognosis were identified.10 This proposal
also implies that adjuvant chemotherapy for patients with high
risk for poor outcome with stage IA NSCLC may be useful for
improving survival in this population.
The major subtypes of adenocarcinoma identified by
the world health organization (WHO) consist of bronchioloal-
veolar carcinoma (BAC), and acinar, papillary or solid tu-
mors with mucin. BAC is defined as a noninvasive tumor that
has lepidic spread—i.e., replacement of the bronchiolar or
alveolar epithelium by tumor cells without stromal, vascular
or pleural invasion and typically has a good prognosis.11,12
However, in practice, the majority of tumors consist of
mixtures of two or more subtypes. Tumors with BAC com-
ponents are classified as mixed type adenocarcinomas with a
BAC component, the prognosis for which reportedly worsens
along with the degree of non-BAC components.13,14
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Mutations within the tyrosine kinase domain of the
epidermal growth factor receptor (EGFR) gene are character-
istic of adenocarcinomas of the lung. EGFR mutations have
been reported to be more frequent in adenocarcinomas having
BAC components.15,16 Furthermore, the EGFR mutation has
been reported to be a good prognostic factor for lung adeno-
carcinoma compared with the EGFR wild-type, although this
is still controversial.17–19 Taken together, for the purpose of
focusing on candidates for adjuvant chemotherapy, it is
important to know the degree of non-BAC components, the
EGFR mutation status, or preferably, both, as potential risk
factors for an unfavorable clinical outcome in stage IA
adenocarcinoma of the lung equal to or less than 20 mm in
diameter.
In this study, we reviewed the clinical data of 127
patients with stage IA adenocarcinoma of the lung 20 mm
in diameter and performed a quantitative estimation of the
non-BAC component in the tumor and an examination EGFR
mutation. Subsequently, we retrospectively analyzed the risk
factors for recurrence and poor prognosis after surgery in this
population.
PATIENTS AND METHODS
Patients
Between January 1995 and December 2002, 734 con-
secutive patients with NSCLC underwent pulmonary resec-
tions at the Department of Cancer and Thoracic Surgery,
Okayama University Hospital. Among them, 127 patients
with pathologic stage IA adenocarcinoma of the lung 20
mm in diameter who had undergone a lobectomy with me-
diastinal lymph node dissection as a complete resection were
included in the current study. Fifty-eight were male and 69
were female with a median age of 65 years (range 38–84
years). The primary treatment in this group was pulmonary
resection without chemotherapy or radiotherapy before sur-
gery. Never-smokers were defined as a lifetime exposure of
100 cigarettes or less, ever-smokers were those with lifetime
exposure of more than 100 cigarettes. Institutional review
FIGURE 1. Histology of mixed ade-
nocarcinoma with BAC component
(Table 3, patient No. 6). A, Hema-
toxylin and eosin staining (10
magnification). B, Schema of the
tumor components. Non-BAC com-
ponent percentage calculated by
NIH image J software was 58.0%.
TABLE 1. Characteristics of Patients According to the Non-BAC Component Percentage
Subsets
Group I
(n  26)
Group II
(n  46)
Group III
(n  18)
Group IV
(n  37)
Non-BAC component (%) 0 0, 50 50, 100 100
Age 63.5  9.1 61.9  10.0 65.6  12.8 64.3  8.9
Sex (male/female) 8/18 (30.8%) 17/29 (37.0%) 11/7 (61.1%) 22/15 (59.5%)
Smoking (never/ever) 18/8 (69.2%) 33/13 (71.7%) 7/11 (38.9%) 14/23 (37.8%)
EGFR mutation () 13/13 (50.0%) 28/18 (60.9%) 9/9 (50.0%) 14/23 (37.8%)
EGFR, epidermal growth factor receptor.
TABLE 2. Relationship between EGFR Mutation and
Clinicopathological Variables in Patients With Stage IA
Lung Adenocarcinoma 20 mm in Diameter
Variables and Subsets (n) No.
No. of EGFR
Mutation Cases (%) p
Age (yrs)
64 71 36 (12.7%) 0.94
64 56 28 (50.0%)
Sex
Male 58 21 (36.2%) 0.0034
Female 69 43 (62.3%)
Smoking status
Ever smoker 55 18 (32.7%) 0.0005
Never smoker 72 46 (63.9%)
Serum CEA level (ng/ml)*
5.0 14 5 (43.9%) 0.28
5.0 112 58 (51.8%)
Tumor size (mm)
15 56 29 (51.8%) 0.92
15 71 35 (49.3%)
Presence of BAC component
Yes 37 14 (37.8%) 0.070
No 90 50 (55.6%)
EGFR, epidermal growth factor receptor; CEA, carcinoembryonic antigen; BAC,
bronchioloalveolar carcinoma.
*The serum CEA level was not evaluated in one patient.
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board permission and informed consent were obtained for all
patients.
Clinical Data
The following clinicopathologic variables were evalu-
ated: age, sex, smoking status, preoperative serum carcino-
embryonic antigen (CEA) level, pathologic tumor size, the
non-BAC component percentage, and EGFR mutation status.
The cutoff CEA level was set at 5.0 ng/ml between the
normal and elevated groups. Clinicopathologic staging was
determined according to the tumor-node-metastasis classifi-
cation of malignant tumors of the International Union against
Cancer.20 Pathologic finding including BAC were determined
based on WHO classification as mentioned.11
Patients were examined at the outpatient clinic at least
every 6 months for 2 years after surgery and annually there-
after. All patients underwent a complete blood count, blood
chemistry analysis, plain chest radiograph, measurement of
serum CEA level, and a computed tomography (CT) scan of
the chest and abdomen to screen for recurrent disease when
appropriate. Biopsies of new lesions suspected to be recur-
rences were performed, if possible, and the attending physi-
cian made the final diagnosis regarding relapse. The overall
survival (OS) and the disease-free survival (DFS) periods
were calculated from the date of surgery until the date of
death or the last follow-up for OS, and the date of recurrence
and death or the last follow-up for DFS.
Analysis of Area of Non-BAC Component
with National Institutes of Health (NIH)
Image J Software
Maximally cut surface specimens of tumor tissue sam-
ples were formalin-fixed and paraffin-embedded. These sam-
ples were observed under BIOZERO BZ-8000 microscopy
(Keyence, Osaka) at a 10 magnification and the percentage
of BAC and non-BAC components was analyzed with NIH
image J software (1.38), which is freely available from the
NIH Website (http://rsb.info.nih.gov/ij/).
DNA Extraction and Mutation Analyses of the
EGFR Gene
The DNAs of 20 frozen lesions were isolated by diges-
tion with proteinase K followed by phenol-chloroform (1:1)
extraction and ethanol precipitation from frozen specimen.21
TABLE 3. Information of Patients Who Died
No. Recurrence
Age
(yrs) Sex Smoking
CEA
(ng/ml)
T Size
(mm)
Non-BAC
Component (%) EGFR
1 Yes 68 Male Ever 5.9 9 100 WT
2 Yes 76 Male Ever 18.2 14 100 WT
3 Yes 56 Male Ever 1.7 20 100 Exon19 del
4 Yes 71 Female Ever 15.2 18 100 Exon19 del
5 Yes 65 Female Never 1.1 15 100 Exon21 L858R
6 Yes 70 Male Ever 1.4 15 58.0 WT
7 Yes 71 Male Ever 2.1 20 85.5 WT
8 Yes 69 Male Ever 6.1 16 54.2 Exon19 del
9 No 65 Male Ever 3.5 18 100 WT
10 No 72 Male Ever 4.5 15 100 WT
11 No 84 Male Ever 6.2 16 55.2 WT
12 No 81 Male Ever 8.9 18 62.7 Exon19 del
13 No 84 Male Never 3.2 20 0 WT
14 No 66 Female Never 1.7 17 0 WT
CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; WT, wild-type; del, deletion.
TABLE 4. Uni- and Multi-variate Analysis for Recurrence and Survival
Variables
Recurrence
Univariate
p
Multivariate
pHR (95% CI) HR (95% CI)
Age (64 vs. 64) 3.82 (0.83–1.75) 0.086 2.38 (0.48–11.8) 0.29
Sex (male vs. female) 2.11 (0.62–7.21) 0.23 2.52 (0.35–18.2) 0.36
Smoking status (ever vs. never) 3.64 (0.97–13.7) 0.057 3.15 (0.34–29.1) 0.31
CEA level (5.0 vs. 5.0) 5.28 (1.54–18.1) 0.008 3.00 (0.65–13.8) 0.16
Tumor size (15 vs. 15) 1.15 (0.35–3.76) 0.82 1.64 (0.45–5.99) 0.46
Non-BAC component (50% vs. 50%) 14.4 (1.85–112.8) 0.011 10.6 (1.27–88.2) 0.029
EGFR mutation status (yes vs. no) 1.19 (0.36–3.90) 0.77 1.42 (0.38–5.29) 0.60
HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor.
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For the 107 lesions that were formalin fixed and paraffin
embedded, DNAs were isolated by DEXPAT (TaKaRa,
Shiga, Japan) following the manufacturer’s instructions.
EGFR mutations were examined limited to exon19 deletions
and exon21 L858R point mutations by mutant-enriched poly-
merase chain reaction (PCR) assays as described previous-
ly.22 Mutant-enriched PCR is a two-step PCR with intermit-
tent restriction digestion to eliminate wild-type genes
selectively, thus enriching the mutated genes at a high sen-
sitivity. The product of the amplification by both the methods
was analyzed with 12% polyacrylamide gel electrophoresis
(PAGE) via ethidium bromide staining. The common dele-
tions of exon19 were distinguished from the wild-type based
on PCR product length polymorphisms using 12% PAGE.
For exon21, Sau96I digestion which can specifically digest
the mutant type was performed before 12% PAGE. These
methods are predicted to detect approximately 85% of EGFR
tyrosine kinase domain mutations.23–25
Statistical Analysis
Differences in significance among the categorized
groups were compared using Fisher exact test or 2 tests
when appropriate. Uni- and multi-variate analyses for rela-
tionships between survival and clinicopathologic variables
were performed using a Cox proportional hazards model.
Survival curves were drawn using the Kaplan–Meier method
which was analyzed with the log-rank test. All data were
analyzed using StatView® 5.0 Program for Windows (SAS
Institute Inc., Cary, NC). All statistical tests were two-sided,
and probability values 0.05 were regarded as statistically
significant.
RESULTS
The Status of Non-BAC Component
and EGFR Mutation
The proportion of BAC and non-BAC components was
determined using NIH image J software (Figure 1). On the
basis of the non-BAC component percentage, all the tumors
of the 127 patients were classified into four categories: those
with BAC (group I, 26 patients), mixed subtype with  50%
BAC (group II, 46 patients), mixed subtype with50% BAC
(group III, 18 patients), and mixed subtype with all non-BAC
components or a pure pattern of one of the non-BAC patterns
(group IV, 37 patients). The patient characteristics of each
group are shown in Table 1. EGFR mutations were observed
in 64 patients (50.4%), 38 as exon19 deletions and 26 as an
L858R point mutation. The relationship between EGFR mu-
tation and clinicopathologic factors is shown in Table 2.
EGFR mutations were more frequently found in the female-
sex (p 0.0034) and never-smokers (p 0.0005) and tended
to be frequently found in cases with BAC components (group
I, II, and III) (p  0.070).
Risk Factors for Recurrence and
Poor Prognosis
By March 2007, 14 patients (11.0%) died in clinical
course and 11 patients (8.7%) developed recurrences after
surgical resection. The median follow-up time among the
surviving patients was 67 months (range, 12–134 months).
The details of the patients who died are shown in Table 3. Of
the total study population, the 5-year OS and DFS rates were
92.9% and 91.3%, respectively. In this study, the status of the
non-BAC component was divided into two groups: high
non-BAC component type (50%) and low non-BAC com-
ponent type (50%), following the classification of previous
studies.13,26 Based on univariate analyses, high CEA level
(hazard ratio [HR]  5.28, 95% confidence interval [CI]:
1.54–18.1, p  0.008) and high non-BAC component type
(HR  14.4, 95% CI: 1.85–112.8, p  0.011) are risk factors
significantly associated with recurrence. No significant dif-
ferences in disease recurrence were observed for age, sex,
smoking status, pathologic tumor size, or EGFR mutations
status. Multivariate analysis indicated that high non-BAC com-
ponent type was the only independent factor associated with
recurrence (HR  10.6, 95%CI: 1.27–88.2, p  0.029). With
regard to survival, univariate analyses indicated that high age
(OS; HR  11.4, 95% CI: 1.49–90.9, p  0.019 and DFS;
HR  6.41, 95% CI: 1.47–27.8, p  0.014), male sex (OS;
HR  4.76, 95% CI: 1.33–17.1, p  0.017 and DFS; HR 
3.08, 95% CI: 1.08–8.76, p 0.035), ever smoking status (OS;
HR  5.42, 95% CI: 1.51–19.5, p  0.0096 and DFS; HR 
3.50, 95% CI: 1.23–10.0, p  0.019), high CEA level (OS;
HR  6.98, 95% CI: 2.42–20.1, p  0.0003 and DFS; HR 
5.06, 95% CI: 1.87–13.7, p  0.0014), and high non-BAC
TABLE 4. Continued
Overall Survival Disease-Free Survival
Univariate
p
Multivariate
p
Univariate
p
Multivariate
pHR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
11.4 (1.49–90.9) 0.019 10.2 (1.29–83.3) 0.028 6.41 (1.47–27.8) 0.014 5.62 (1.24–25.6) 0.025
4.76 (1.33–17.1) 0.017 2.34 (0.14–39.7) 0.56 3.08 (1.08–8.76) 0.035 1.77 (0.19–16.2) 0.61
5.42 (1.51–19.5) 0.0096 1.45 (0.037–13.1) 0.80 3.50 (1.23–10.0) 0.019 1.41 (0.14–1.45) 0.77
6.98 (2.42–20.1) 0.0003 3.17 (0.88–11.4) 0.077 5.06 (1.87–13.7) 0.0014 2.37 (0.72–7.74) 0.15
2.55 (0.85–7.62) 0.094 1.45 (0.47–4.70) 0.49 1.99 (0.76–5.22) 0.16 1.15 (0.42–3.15) 0.78
8.48 (1.90–37.9) 0.0051 5.00 (1.03–24.2) 0.046 6.72 (1.93–23.4) 0.0028 4.42 (1.18–16.6) 0.027
1.73 (0.58–5.20) 0.33 1.60 (0.49–5.23) 0.44 1.86 (0.69–5.04) 0.22 1.55 (0.54–4.49) 0.42
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component type (OS; HR  8.48, 95% CI: 1.90–37.9, p 
0.0051 and DFS; HR  6.72, 95% CI: 1.93–23.4, p  0.0028)
were significantly related to the poor OS and DFS. No signifi-
cant differences in survival were observed according to patho-
logic tumor size, or EGFR mutations. Multivariate analysis
indicated that high age (OS; HR  10.2, 95% CI: 1.29–83.3,
p  0.028, and DFS; HR  5.62, 95% CI: 1.24–25.6, p 
0.025) and high non-BAC component type (OS; HR  5.00,
95% CI: 1.03–24.2 p  0.046 and DFS; HR  4.42, 95% CI:
1.18–16.6, p 0.027) were independent factors associated with
poor OS and DFS (Table 4).
Kaplan–Meier survival curves stratified by non-BAC
component level and EGFR mutation are shown in Figure 2.
As consistent with the results with the Cox proportional
hazards model, OS and DFS were significantly shorter in
patients with high non-BAC component type than those with
low non-BAC component type (OS, p  0. 0.0008 and DFS,
p  0.0005). On the other hand, there was no difference in
OS and DFS periods between patients with EGFR mutant and
wild-type.
DISCUSSION
Recent randomized phase III trials have shown that
patients with stage IB–IIIA NSCLCs are candidates for ad-
juvant chemotherapy after complete surgical resection.7–9
The indications for adjuvant chemotherapy among patients
with stage IA NSCLC, on the other hand, are still under
debate, despite the performance of subset analyses in certain
randomized trials.10 To select candidates for adjuvant chemo-
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FIGURE 2. Kaplan–Meier survival curves. A, Overall survival stratified by non-BAC component level. B, Disease-free survival
stratified by non-BAC component level. C, Overall survival stratified by EGFR mutation. D, Disease-free survival stratified by
EGFR mutation.
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therapy among stage IA patients with equal to or less than 2 cm
tumors whose prognosis is supposed to be excellent, two issues
should be identified: (1) the risk factors for poor outcome and (2)
the predictors of efficacy of the therapeutic agents used. This
study was conducted to clarify the former issue.
We previously reported the poor differentiation to be a
risk factor for recurrence and poor prognosis in patients with
stage IA NSCLC20 mm in diameter.27 However, the grade of
tumor differentiation is based on subjective criteria and is not
officially defined. Thus, the assessment of risk factors based on
more objective parameters is necessary for precise assessment.
For this study, we limited the subjects to adenocarcinomas
because this subtype is the most common among the lung
cancers with well defined characteristics in the WHO criteria.
Previous studies examined the impact of non-BAC or
BAC component on the clinical outcome of patients with lung
adenocarcinomas. Sakao and his colleagues reported that a high
non-BAC component was strongly associated with poor prog-
nosis in resected adenocarcinoma,14 which suggested that tu-
mors with both BAC and non-BAC components can be subdi-
vided into two groups based on the degree of non-BAC
component. Higashiyama and his colleagues reported that a
ground-glass opacity (GGO) of less than 50% was a risk factor
for lymph node metastasis, advanced stage and poor clinical
outcome in adenocarcinoma of tumor 20 mm in diameter,
although the GGO ratio was determined in a subjective manner
(investigators’ impression). In addition, previous reports have
suggested a GGO of greater than 50% on high-resolution CT
images to be a preoperative indicator of favorable outcome using
NIH image J software26. Therefore, we set the threshold of the
percentage of non-BAC component at 50.0% and used NIH
image J software in this study for objective quantification.
The main result reported here is that the high non-BAC
component type is the only independent risk factor for both
recurrence and a poor prognosis. On the other hand, EGFR
mutation had no correlation with recurrence or survival on either
univariate or multivariate analysis. EGFR mutation tended to be
more frequent in tumors with a BAC component, as shown in
previous studies.28,29 These results suggest that the EGFR mu-
tation is a surrogate factor of the BAC component not directly
related to prognosis. Taken together, the degree of non-BAC
component seems to be a useful indicator of a need for postop-
erative adjuvant chemotherapy in patients with small lung ade-
nocarcinoma.
In conclusion, we found that tumors with high percentage
of non-BAC component, but not EGFR mutation, are a risk
factor for both recurrence and poor prognosis in patients with
stage IA lung adenocarcinoma 20 mm in diameter. Whereas
randomized prospective studies are mandatory, the status of
non-BAC component can be used as a suggestive indictor for
adjuvant chemotherapy in small adenocarcinoma of the lung.
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